In this study, we identified a number of conventional chemotherapeutic agents and the Aurora B inhibitor barasertib, which, when combined with the MEK inhibitor selumetinib, resulted in enhanced efficacy in human tumour xenograft models. This evidence concerns the gene AURKB and neoplasm.